Mitogen Activated Protein Kinase 3 - Pipeline Review, H2 2016 - Therapeutics Assessment by Drug Target, MoA, RoA & Molecule Type - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Mitogen Activated Protein Kinase 3 - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Mitogen Activated Protein Kinase 3, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mitogen Activated Protein Kinase 3 and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • AGV Discovery SAS
  • Eli Lilly and Company
  • Kura Oncology Inc
  • Merck & Co Inc
  • Merck KGaA

Key Topics Covered:

  1. Introduction
  2. Mitogen Activated Protein Kinase 3 Overview
  3. Therapeutics Development
  4. Pipeline Products for Mitogen Activated Protein Kinase 3 - Overview
  5. Pipeline Products for Mitogen Activated Protein Kinase 3 - Comparative Analysis
  6. Mitogen Activated Protein Kinase 3 - Therapeutics under Development by Companies
  7. Mitogen Activated Protein Kinase 3 - Therapeutics under Investigation by Universities/Institutes
  8. Mitogen Activated Protein Kinase 3 - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Mitogen Activated Protein Kinase 3 - Products under Development by Companies
  13. Mitogen Activated Protein Kinase 3 - Products under Investigation by Universities/Institutes
  14. Mitogen Activated Protein Kinase 3 - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/6w4lxl/mitogen_activated

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Enzymes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Enzymes